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Mechanism of G protein-coupled receptor (GPCR)
activationand theirmodulationby functionallydistinct
ligands remains elusive. Using the technique of amide
hydrogen/deuterium exchange coupled with mass
spectrometry, we examined the ligand-induced
changes in conformational states and stability within
the beta-2-adrenergic receptor (b2AR). Differential
HDX reveals ligand-specific alterations in the energy
landscape of the receptor’s conformational en-
semble. The inverse agonists timolol and carazolol
were found to be most stabilizing even compared
with the antagonist alprenolol, notably in intracellular
regions where G proteins are proposed to bind, while
the agonist isoproterenol induced the largest degree
of conformationalmobility. Thepartial agonist clenbu-
terol displayed conformational effects found in both
the inverse agonists and the agonist. This study high-
lights the regional plasticity of the receptor and char-
acterizes unique conformations spanning the entire
receptor sequence stabilizedby functionally selective
ligands, all of which differ from the profile for the apo
receptor.
INTRODUCTION
G protein-coupled receptors (GPCRs) are highly versatile
signaling proteins that are responsible for the majority of signal
transduction across cellular membranes in response to extracel-
lular hormones and neurotransmitters. These seven-transmem-
brane receptors are the key regulators of many physiological
responses, and as such they represent the most prominent
group of therapeutic targets for a wide range of disorders
(Ma and Zemmel, 2002; Pierce et al., 2002; Overington et al.,
2006; Schwartz and Hubbell, 2008). Signaling by endogenous
or synthetic ligands (agonists) involves specific conformational
changes in GPCRs that propagate from the extracellular ligand
binding pocket into the cytoplasmic side of the receptor,1424 Structure 19, 1424–1432, October 12, 2011 ª2011 Elsevier Ltdpromoting downstream signaling cascades mediated by G
proteins or other intracellular effectors. Many GPCRs, including
the b2AR also maintain some level of basal signaling activity
that does not require the presence of agonist (Yao et al., 2009).
Structurally diverse agonists can vary in efficacy ranging
from partial to full activation of the receptor (Zhang et al.,
2010a). Moreover, some ligands have been described as having
a bias toward recruiting and activating different G proteins
or other intracellular effectors, thus eliciting different physio-
logical responses—a phenomenon referred to as ligand-biased
signaling or functional selectivity (Swaminath et al., 2004,
2005; Urban et al., 2007; Kim et al., 2008; Choi et al., 2010; Griner
et al., 2010). Agonist-mediated signaling can be inhibited by
antagonists and inverse agonists, where inverse agonists have
the capacity to reduce basal signaling.
This spectrum of functionally distinct ligands, most extensively
studied in the b2AR (Swaminath et al., 2005; Yao et al., 2009),
leads to a concept of multiple conformational states for
receptors, where ligands modify the conformational landscape
and thus shift the equilibrium from one state(s) of the ensemble
to another (Lefkowitz et al., 1993; Kobilka andDeupi, 2007). Exis-
tence of such ensembles of states has been a major obstacle in
structure determination efforts for GPCRs for a long time, allow-
ing crystallization of only the stable receptor with covalently
bound ligand, bovine Rhodopsin (bRho) (Palczewski et al.,
2000). The recent breakthroughs in membrane protein crystal-
lography and massive efforts in GPCR stabilization through
protein engineering and coligand selection has lead to high-
resolution structures of b2AR (Cherezov et al., 2007; Rasmussen
et al., 2007; Hanson et al., 2008; Wacker et al., 2010) and later
b1AR, adenosine A2a, dopamine D3, and chemokine CXCR4
receptors (Jaakola et al., 2008; Warne et al., 2008; Chien et al.,
2010; Wu et al., 2010). In addition to these structures stabilized
in the inactive form by corresponding inverse agonists or antag-
onists, structures of active state GPCR have been obtained for
opsin (a retinal-free bRho) (Park et al., 2008; Scheerer et al.,
2008), and most recently for b2AR (Rasmussen et al., 2011)
and adenosine A2a receptors (Lebon et al., 2011; Xu et al.,
2011). While all these structures provide an important 3D
framework for understanding agonist binding and activation-
related changes in the complex, each of them still represents
a single frozen state, giving little information about the wholeAll rights reserved
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Modulator Effects on GPCR Conformation Using HDXconformational ensemble. For example, conformations of b2AR
cocrystals with various ligands, including antagonists, inverse
agonists (Hanson et al., 2008; Wacker et al., 2010), and full
agonists (Rosenbaum et al., 2011) were found to be practically
undistinguishable from the originally described single inactive
state (Cherezov et al., 2007; Rasmussen et al., 2007), until
their switch into an active-like state was stabilized by binding
of a G protein mimicking nanobody from the intracellular side
(Rasmussen et al., 2011). Similarly, cocrystal structures of
b1AR (Warne et al., 2011) with full agonists showed only modest
changes in the ligand binding region while keeping the intracel-
lular G protein binding site in an inactive conformation.
Understanding of GPCR activation mechanisms would greatly
benefit from synergistic biophysical and biochemical methods
capable of probing dynamics and ensemble fluctuations of local
conformational states that define the overall plasticity of the
receptor in the presence and absence of modulators. In addition,
biochemical approaches may give insights into conformational
states of some important functional elements of GPCRs often
missing in the crystal structures (e.g., N and C termini and intra-
cellular loop 3 [ICL3]) or potentially distorted by crystal packing.
Though previous mutagenesis and biochemical studies sug-
gested some local elements of ligand-dependent variations in
both extracellular and intracellular regions of b2AR (Gether
et al., 1997; Ghanouni et al., 2001; Jensen et al., 2001; Yao
et al., 2009; Bokoch et al., 2010; Reiner et al., 2010), there is
a great demand for an experimental approach capturing the
overall picture of local conformational changes and stability vari-
ations in the receptor upon ligand binding. To address this void
of information, we probed the local stability of b2AR using
hydrogen/deuterium exchange coupled with mass spectrometry
(HDX-MS). The bottom-up HDX-MS approach involves exposing
intact protein to deuterium oxide at various time intervals, and
this is followed by proteolysis and mass analysis under slow
exchange conditions (low pH and low temperature to preserve
in-exchanged deuterium). This technique allows localized
sequence-specific measurements of amide hydrogen exchange
to accurately quantify the extent of protection of main chain
amide protons (Englander, 2006). Protection against HDX
increases for amides involved in strong hydrogen bonding (i.e.,
in secondary structures), as well as in amides buried in the
protein interior or interface with other proteins. Measurements
of the time dependence profile for each peptide also gives
insight into long-term local stability or unfolding rate monitored
for up to 18 hr (Chalmers et al., 2011a). Most importantly, key
insights into the protein binding interactions or conformational
state alterations can be obtained by comparing HDX profiles in
different complexes (Zhang et al., 2010a). Typically HDX-MS
does not characterize discrete states of the conformational
ensemble, but it is capable of detecting changes of equilibrium
between these states from complex to complex (differential
HDX). Deuterium uptake for a given region of the receptor results
from an average deuterium uptake for all conformational states
sampled, including rare folding/unfolding events. Recently, this
technique was carefully optimized for analysis of integral mem-
brane receptors in a study with the b2AR-carazolol complex
(Zhang et al., 2010b).
In the study presented here, HDX analysis was performed on
apo-b2AR and five b2AR-ligand complexes representing distinctStructure 19, 1424–1functional classes: a full agonist isoproterenol, a partial agonist
clenbuterol, an antagonist alprenolol, and two inverse agonists
carazolol and timolol. Receptor bound to inverse agonists
and antagonist shows increased local stability to many intracel-
lular and extracellular regions. In contrast the agonist shows
decreased local stability at intracellular regions previously
shown to interact with G proteins. The timescale of the
agonist-induced decrease in stability at helix VIII indicates this
region may be involved in internalization. The data for clenbu-
terol, a classic ‘‘partial agonist,’’ more closely resembles that
of the inverse agonists and antagonist than that of the full agonist
and may provide conformational clues to its pharmacology.
Results from these studies provide a comprehensive view of
variations in local stability in a GPCR upon binding of distinct
ligands spanning the range of all functional modulator classes.
In addition, these studies examine structural elements across
all three regions of this receptor (intracellular, transmembrane,
and extracellular) in the apo state as well as the agonist bound
state.
RESULTS
Coverage and Trends in Deuterium Exchange
While HDX analysis of membrane proteins remains challenging,
over 71% of the amino acid sequence of the b2AR was covered
across all complexes and all HDX time points (see Figure S1
available online) (i.e., peptides were only included if they were
resolved across all time points in the presence of every ligand
and for the apo receptor). Most importantly, consensus
coverage included all intracellular and extracellular regions of
the receptor with the only exception being extracellular loop 1
(ECL1). Deuterium exchange of apo b2AR was monitored over
nine time points ranging from 10 s to 18 hr of exposure to heavy
water (Figure 1).
For most of the peptides detected in the HDX experiment, the
solvent exchange reaches a plateau within the first minute of
exposure to heavy water and does not change substantially
over 18 hr of continued exposure to heavy water, indicating
that initially protected amide protons in the corresponding
structural elements remain protected during the whole course
of the experiment. A notable exception is a peptide (326–332),
representative of helix VIII, which is fully protected in the first
minute of D2O exposure, but allows slow exchange at a
steady rate of about 0.0005 s1, reaching 80% in 18 hr for the
b2AR-carazolol complex (and 100% for the b2AR-isoproterenol
complex). This result suggests that, while helix VIII is pre-
dominately structured, it is less stable than other intra- and extra-
cellular secondary structure elements, exhibiting elevated rates
of localized unfolding as compared, for example, with ECL2
helix.
As expected, lower deuterium incorporation was observed for
peptides from a helices found in the transmembrane core,
a region of the receptor with minimal solvent accessibility. Peptic
peptides originating from the N-terminal region of the receptor
construct show unusual negative trends in their deuterium
uptake plots. The N terminus of the protein construct contains
a Flag affinity tag important for receptor purification. However,
peptic peptides that contain portions of the affinity tags such
as these typically show unusual HDX behavior. HDX data from432, October 12, 2011 ª2011 Elsevier Ltd All rights reserved 1425
225-240+3
Predicted HDX(3D structure), %
H
D
X(
30
se
c)
,%
135-144+2
147-155+3
335-339+2
243-264+3
267-279+2
176-184+2
176-193+2
Na+
13-31+4
Accessibility of amide H in the 2AR constructβ
Figure 2. Analysis of Amide Proton Accessibility in the Context of
the b2AR-Carazolol Crystal Structure (PDB: 2rh1)
Percentage of hydrogen-deuterium exchange for each nonredundant peptide
derived from HDX-MS data is plotted against the predicted ratio of accessible
amide protons in this peptide calculated from crystal structure. The linear
regression fits the data (blue line) with R2 = 0.87 and rmsd = 10%. The amide
proton in the crystal structure is considered inaccessible if it (1) forms
a hydrogen bond within the protein structure, (2) is buried within protein, or (3)
belongs to the lipid bilayer (colored blue ribbon). Representative 3D structural
elements are shown with the accessible amines of the peptide highlighted by
a red sphere and inaccessible by blue spheres. For ‘‘176-193 +2’’ peptide, the
binding site of Na+ ion is shown by magenta sphere. Hydrogen bonding was
assigned and the figure was prepared using ICM software (Molsoft LLC).
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Figure 1. HDX Profile of apo b2AR Mapped to a Modified Structure
Derived from PDB 2rh1
The modified structure is based on PDB 2RH1 but has ICL3 and the termini
regions arbitrarily grafted in to accommodate the sequence coverage in this
study. The color gradient is used to depict the percentage of corrected
deuterium uptake observed in peptides that overlap with regions of the
receptor sequence. The percentage of deuterium uptake values represents an
average percent across all nine time points ranging from 10 s to 18 hr. White
indicates the regions of the sequence that were not consistently resolved in
this study. Although these data are for the apo protein, carazolol is shown as
purple spheres for a visual reference of the binding pocket. The coverage map
for the receptor is shown in Figure S1.
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Modulator Effects on GPCR Conformation Using HDXpeptides in this region were removed from this study as they are
not representative of the receptor.
Correlation with Reported Crystal Structures
Detailed quantitative analysis of HDX data for the b2AR-carazolol
complex shows an accurate correlation between experimental
levels of exchange in the detergent solution over the course of
the experiment and physical exchangeability of the main-chain
amide protons predicted from the 3D crystal structure of this
complex (PDB: 2rh1) (Figure 2). In the structure-based predic-
tion, an amide proton was deemed protected if it was involved
in an intramolecular hydrogen bonding interaction, buried in
the protein interior or within the lipid membrane (see Experi-
mental Procedures). The structure-based predictions correlate
well with the experimental HDX rate (R2 = 0.87 and rmsd =
10%), which is close to a single residue accuracy for most
peptides studied here. The most significant deviation in terms
of absolute number of exchanging amide protons (three less1426 Structure 19, 1424–1432, October 12, 2011 ª2011 Elsevier Ltdexchanging protons than predicted) was found for the ‘‘176-
193 +2’’ peptide, most likely because this domain comprises
a known binding site for Na+ ion (Warne et al., 2008) which can
significantly impact the HDX rate of the peptide.
This structure-based analysis for the b2AR-carazolol complex
leads to several important observations. First, it confirms
close similarity between the b2AR conformational states in deter-
gent solution of HDX experiments and in the crystalline form.
Second, the accurate correlation between HDX data and struc-
tural predictions that implied full protection against HDX in the
membrane region suggest that detergents used in this study fully
protect the same area of the b2AR as the lipid membrane. Third,
our analysis suggests that the N terminus and ICL3 regions,
which are missing or unstructured in the b2AR crystal structures,
are also unstructured in the detergent solution, as these regions
lack significant protection against exchange even at early time
points. At the same time, the number of exchanged hydrogens
in the other loops (ECL1, ECL2, ECL3, and ICL2) accurately
corresponds to the number of accessible amide protons in the
b2AR crystal structure, suggesting that these structural elements
are highly stable in solution.
Modulator Perturbation to the b2AR
The most important insight into b2AR activation mechanism can
be obtained from differential HDX profiles comparing five
receptor-ligand complexes to the apo receptor. Statistically
significant differences in the HDX profiles were observed for
each of the five receptor-ligand complexes. The perturbation
maps for each of the complexes are shown in the supplemental
information (Figures S2–S4). These perturbation data areAll rights reserved
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Region Peptide 
(charge) 
Isoproterenol
110-300 nM 
Clenbuterol
24 nM 
Alprenolol
0.9 nM 
Timolol
0.2 nM 
Carazolol
0.02-0.1 nM 
N term 19-39 (+4) -2 ± 2 -1 ± 4 -1 ± 2 -7 ± 4 -11 ± 3 
ICL1 62-77 (+4) -1 ± 2 -8 ± 3 -9 ± 2 -8 ± 3 -13 ± 2 
ICL1 73-78 (+1) 0 ± 1 -1 ± 3 -9 ± 3 -4 ± 1 -6 ± 1 
TM2 93-103 (+2) 0 ± 1 -1 ± 1 -1 ± 1 1 ± 1 0 ± 1 
ICL2 141-152 (+2) -4 ± 4 -11 ± 4 -16 ± 4 -11 ± 3 -20 ± 3 
TM4 172-181 (+2) 0 ± 1 -2 ± 1 -1 ± 1 -1 ± 1 -1 ± 1 
ECL2 182-187 (+2) 0 ± 1 -7 ± 3 -20 ± 5 -7 ± 2 -8 ± 1 
ECL2 182-201 (+3) 1 ± 1 -4 ± 1 -7 ± 1 -3 ± 1 -4 ± 1 
ICL3 233-248 (+4) 1 ± 2 -3 ± 4 -10 ± 4 -7 ± 3 -13 ± 2 
ICL3 249-257 (+3) 0 ± 2 -10 ± 3 -22 ± 6 -5 ± 3 -9 ± 2 
ICL3 258-269 (+3) 4 ± 1 -5 ± 3 -13 ± 4 -2 ± 1 -3 ± 1 
ECL3 284-295 (+3) 1 ± 4 -5 ± 2 -4 ± 2 -5 ± 3 -10 ± 2 
TM7 309-319 (+2) -1 ± 1 -3 ± 1 -1 ± 1 -2 ± 1 -2 ± 1 
H VIII 320-325 (+2) 6 ± 1 2 ± 3 -7 ± 5 -6 ± 1 -3 ± 1 
H VIII * 326-332 (+2) 2 ± 1 1 ± 1 1 ± 1 1 ± 1 0 ± 1 
Figure 3. Differential HDX Data for Selected
Peptides Spanning Secondary Structural
Elements in b2AR
Average percentage deuterium uptake differences
between apo-b2AR and each of the ligand
complexes are shown for the 10 s time point only
with their propagated standard errors. Dissocia-
tion constants from the literature are listed under
each ligand: isoproterenol (Macchia et al., 1993;
Gether et al., 1995), clenbuterol (To¨rneke et al.,
1998), alprenolol and timolol (Baker, 2005), and
carazolol (Heald et al., 1983; Zheng et al., 1994).
Peptides with average percentage deuterium
uptake differences ranging from5% to3% and
3 to 5%were subjected to an unpaired one-tailed t
test to determine if differences were significant,
otherwise percentage of deuterium differences
are color coded according to the key (white indi-
cates no significant change). *Changes in deute-
rium uptake are observed for this peptide at longer
time points (see Figures S5 and S6). Data for all
time points are shown in Figure S5.
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Modulator Effects on GPCR Conformation Using HDXtabularized in Figures S5 (the 10 s data are shown in Figure 3) and
are overlaid onto the b2AR crystal structure for each ligand
complex (Figure 4) using a color gradient to depict the difference
in the average percentage deuterium uptake of each ligand
complex from apo. Protection to deuterium exchange was
observed in many regions remote from the ligand binding site.
Specific variations in the HDX profiles were detected for all extra-
cellular and intracellular regions of the b2AR. Lack of changes in
the peptides that belong to transmembrane helical regions
(including the ligand binding pocket) indicates that these regions
remain protected in all ligand complexes as well as in the apo
structure, although, given the low levels of deuterium uptake,
subtle conformational alterations in this region would be difficult
to detect over the timescale studied here.
Some notable trends between different classes of ligands are
apparent from Figure 3. Across all receptor-ligand complexes,Full Agonist
(Isoproterenol)
Partial Agonist
(Clenbuterol)
Antagonist
(Alprenolol)
Partial Inv. Agonist
(Timolol)
ECL2
ICL3 ICL1
ECL3
ICL2 Helix VIII
Perturbation View of All Timepoints
Key
-20 -10 -5 ns +5 +10
Structure 19, 1424–1both intracellular and extracellular regions show significant
differences in the extent of perturbation in HDX behavior
between ligand classes. The most general trend is stabilization
of all b2AR regions by antagonists and inverse agonists, which
is most pronounced for carazolol binding.
Ligand-Induced Perturbation of the Extracellular Region
On the extracellular region of the receptor, binding of inverse
agonists and antagonist afforded the most pronounced stabi-
lizing effect on ECL2 and ECL3. The ECL2, which links helices
IV and V, has a more extensive architecture than other loops
and contains a short a-helical segment. Protection from HDX
increased in peptides covering the a helix and flanking regions
for b2AR in complex with antagonist and inverse agonists,
indicating increased stabilization of the secondary structure.
This ligand-induced stabilization can be explained by directPartial Inv. Agonist
(Carazolol)
Figure4. HDXDataOverlaidontoaModified
Crystal Structure for b2AR
The HDX data are shown using color gradients
where the differences in the average percentage
deuterium uptake across all time points between
the apo and ligand bound receptor for peptides in
a given region of the receptor sequence are
assigned a color as shown in the key, and then
overlaid onto the structure. Here, white indicates
regions of the receptor that were not resolved in
the HDX experiment, and gray indicates no
significant change. Ligand structures are indi-
cated above the structures.
432, October 12, 2011 ª2011 Elsevier Ltd All rights reserved 1427
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Modulator Effects on GPCR Conformation Using HDXhydrophobic contacts between ligands and Phe193 of ECL2
found in the corresponding crystal structures (Cherezov et al.,
2007; Hanson et al., 2008; Wacker et al., 2010); a similar contact
was predicted for the partial agonist clenbuterol as well (Katritch
et al., 2009). In contrast, binding of full agonists like isoproterenol
is known to be accompanied by substantial (1–2 A˚) inward shift of
the helix V top portion (Katritch et al., 2009; Rosenbaum et al.,
2011), which apparently brings the ends of ECL2 closer together
and changes the conformation at ECL2. Isoproterenol has the
lowest affinity of all the modulators in this study for the b2AR.
This is a common trend seen for many GPCR agonists, and an
antagonist’s ability to alter the conformation around ECL2 may
confer an advantage in binding pocket competition. The HDX
data provide a conformational component to help account for
ligand affinity and agonist displacement.
Ligand-Induced Perturbation of the Intracellular Region
Some of themost significant increases in protection against HDX
were detected for the ICL2 region, which reaches 20% at 10 s of
exchange for carazolol binding. Indications that ICL2 is a highly
dynamic region come from recent crystal structures of b-adren-
ergic and dopamine receptors, where this loop was found in
either an extended/unstructured state (Cherezov et al., 2007)
or in a highly ordered a-helical conformation with two to three
helical turns (Warne et al., 2008; Chien et al., 2010). Interestingly,
both unstructured and a-helical states of ICL2 were detected in
two asymmetric subunits of dopamine D3 receptor structure
(PDB: 3PBL) (Chien et al., 2010). As these crystal structures
suggest, ICL2 in the a-helical form can help stabilization of the
so called ‘‘ionic lock’’ in GPCRs via involvement of the conserved
Tyr141 of ICL2 in a hydrogen bonding network with D(E)RY motif
in helix III. While protection to exchange in ICL2 was the stron-
gest for the carazolol-b2AR complex, some significant increase
in protection against HDX was conferred by other ligands as
well, including partial agonist clenbuterol, suggesting that these
ligands can also shift equilibrium toward more protected helical
state of ICL2.
HDX data also suggest ICL3’s role as a molecular switch,
where antagonist and inverse agonist complexes have signifi-
cant increase in protection to exchange both to ICL3 and flank-
ing regions of TM helices V and VI. Crystal structures of inactive
and activated states of GPCRs (Rasmussen et al., 2011; Xu et al.,
2011) suggest that helices V and VI undergo large movements
upon GPCR activation, which plays a key role in reshaping G
protein interface of GPCRs. The ICL3 in these crystal structures
is either replaced by T4L fusion protein (Cherezov et al., 2007;
Rasmussen et al., 2011) or remains unstructured (Warne et al.,
2008, 2011). The HDX results demonstrate that binding of antag-
onists and inverse agonists shifts equilibrium toward inactive
states which is characterized by protection to exchange in the
loop. The additional protection can be explained by stabilization
or some elongation of the TM helical structures, as suggested by
recent crystal structures of thermostabilized b1AR (Warne et al.,
2011), or formation of some structural elements in the loop itself.
In contrast to the antagonist, inverse agonists and even the
partial agonist clenbuterol, binding of the full agonist isoproter-
enol shifts equilibrium toward higher accessibility and/or desta-
bilization of ICL3 region. The increase in deuterium exchange
upon binding of full agonist is in good agreement with commonly1428 Structure 19, 1424–1432, October 12, 2011 ª2011 Elsevier Ltdaccepted activation models where helices V and VI undergo
conformational changes opening up the G protein binding
site. In general, binding of the full agonist isoproterenol does
not confer significant protection against HDX to any region
of the receptor while significantly reducing protection to ex-
change (increased exchange) in some of the intracellular regions
including the abovementioned destabilization of ICL3.
Another part of the receptor that shows unusual changes by
agonist binding is the helix VIII region. As we mentioned above,
the helix VIII peptide is almost fully protected in the early HDX
time points (t < 60 s) while allowing slow deuterium exchange
over 18 hr of experiment. Isoproterenol and clenbuterol, a full
agonist and a partial agonist, increase the rate of this slow
exchange. Deuterium uptake values correlate with those seen
for the apo receptor at shorter exchange times (i.e., 10 s) and
diverge to higher deuterium levels, or decreased stability, at
longer exchange times (see Figures S5; Figures 3, 4, and 6), indi-
cating destabilization of this structural element induced by
agonist binding, whereas no statistically significant changes in
HDX were observed in this region for the receptor complexes
with antagonist or inverse agonists (Figures 3 and 4). Even
more importantly, isoproterenol was capable of increasing initial
HDX for a neighboring peptide that covers the junction of TM
helixVIIwith helix VIII, suggesting a likely change in theconforma-
tion of this region. This latter observation is in agreement with
crystal structures of active b2AR (Rasmussen et al., 2011) and
adenosine A2a (Xu et al., 2011), which show dramatic movement
of the intracellular tip of helix VII corresponding to NPxxY motif
compared to inactive structures, resulting in more extended
(i.e., less protected) conformation of VII/VIII helical junction.
Statistical Approaches
The effects of these fivemodulators on ECL2 and ICLs, aswell as
other regions in b2AR, can be seen from the 60 s on-exchange
data displayed in Figures 5 and 6; Figure S13. A Tukey multiple
comparison test was used to determine the significance of
HDX perturbation observed for specific peptides across each
receptor-ligand complex. Each ligand is assigned a number,
I–V, (at the bottom of each chart) and the numbers above the
bars represent those ligands that exhibit a statistically significant
difference (p value < 0.05) between complexes. For example,
differential HDX data for a peptide derived from ECL2 (Figure 5)
reveal that the difference in stability of this region of the receptor
when bound to the full agonist isoproterenol was statistically
significant as compared with the other four complexes (desig-
nated II, III, IV, and V). In addition, HDX profiles of the two
agonists can be statistically differentiated from the other modu-
lators in helix VIII (Figure 6). A significant difference exists
between the conformational landscapes of isoproterenol bound
b2AR and the other four ligands in this study. Note that partial
agonist clenbuterol has a HDX profile that combines some
features of antagonists/inverse agonists on one side and full
agonist isoproterenol on the other. Thus, clenbuterol binding
confers similar level of stabilization to b2AR ICL1, ICL2, and
ICL3 regions as timolol or carazolol, while significantly destabiliz-
ing helix VIII region (though to a lesser extent than full agonist
isoproterenol). This distinct profile of clenbuterol can be ex-
plained by a distinct set of conformational changes for this partial
agonist binding, similar to ligand-specific changes for someAll rights reserved
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Figure 5. Extracellular View of a Modified
Structure of b2AR
Differential HDX data are shown for selected
peptides from three regions of interest at 60 s of
exchange. The charts are annotated with the
results from a Tukey multiple comparison test.
Each ligand is assigned a number (at the top of
each chart) and the numbers in boxes below the
bars correspond to those ligands that exhibit
a significant difference with a p value < 0.05. For
example, in the ECL2 helix isoproterenol is
significantly different from II, III, IV, and V. All error
bars represent standard deviations. Additional
Tukey plots are shown in Figure S6.
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Modulator Effects on GPCR Conformation Using HDXcatechol derivatives (Swaminath et al., 2005) and suggest poten-
tial functional selectivity of this ligand (Urban et al., 2007).
DISCUSSION
Analysis of the entire HDX data set facilitates the emergence
of an overall picture of receptor-agonist interaction. HDX
reveals that agonist binding promotes a shift of the conforma-
tional ensembles of b2AR with higher energetics, specifically
around ICL3 and intracellular helix VIII, while having little impact
on other structural elements of the receptor. This is in contrast
to receptor binding to inverse agonists and antagonists,
which promote increased stability (decreased HDX kinetics)
for intra- and extra- cellular regions of the inactive conforma-I IVIIIII V
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Structure 19, 1424–1432, October 12, 2011 ªtional ensemble of the receptor. These
alterations in the conformational en-
semble likely modulate intracellular sig-
naling by increasing or decreasing
interactions around the b2AR docking
interface with G protein. The timescale
of agonist perturbation at helix VIII mayindicate this region plays a role in receptor internalization
(Figure 6).
The global HDX profile for the partial agonist clenbuterol is
more similar to that of the antagonists/inverse agonists than
that of the full agonist. However, the partial agonist more closely
resembles the apo state than the inverse agonists with regard to
the helix VIII region suggesting a conformational mechanism for
clenbuterol’s partial agonism. The similarity in HDX profiles
between the antagonist and the inverse agonists may suggest
that affinity could play a larger role in differentiating these two
classes of ligands. However, further experiments are necessary
to confirm or reject this hypothesis.
Previous studies assessing conformational alterations to
b2AR have used fluorescent probes to monitor site-specificFigure 6. Intracellular View of a Modified
Structure of b2AR
Differential HDX data are shown for selected
peptides from five regions of interest at 60 s of
exchange. The charts are annotated with the
results from a Tukey multiple comparison test.
Each ligand is assigned a number (at the top of
each chart) and the numbers in boxes below the
bars correspond to those ligands that exhibit
a significant difference with a p value < 0.05. The
deuterium uptake plot for the Helix VIII peptide is
shown as an insert with that peptide’s statistical
analysis. All error bars represent standard devia-
tions. Additional Tukey plots are shown in Fig-
ure S6.
2011 Elsevier Ltd All rights reserved 1429
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Modulator Effects on GPCR Conformation Using HDXalterations, often limited to only a few amino acid side chains.
The HDX study presented here does not involve covalent probes
and simultaneously monitors conformational alterations of the
receptor with detection of >70% of the amino acid sequence.
Although most observed changes in deuterium uptake percent-
ages are subtle when comparing apo to ligand bound receptor,
we demonstrate that these changes are statistically significant,
and as such are expected to be meaningful (Kenakin and Miller,
2010; Rasmussen et al., 2011; Rosenbaum et al., 2011). The
thorough statistical approach used here with randomization of
the analysis of multiple independent replicates at multiple time
points is necessary to detect these types of alterations (Chalm-
ers et al., 2011b).
In summary, these studies have revealed regions of the b2AR
that are involved in receptor modulation by functionally selective
ligands in the absence of an allosteric modulator. Although the
HDX technique is blind to high-resolution alterations of specific
side chains seen in the active state crystal structure or side-chain
motions, these findings indicate that local folding thermody-
namics in intra- and extracellular regions are differentially altered
in response to binding functionally selective ligands, and this is
likely due to ligand-specific conformational selection. These
findings provide further insight into the progress of uncovering
the activation mechanism of GPCR signaling. This study, in
combination with crystal structure determination of the GPCR
b2AR, provides novel insight into structural elements responsible
for controlling function. Receptor conformational selectivity was
illustrated with a range of functionally selective modulators, sug-
gesting a mechanism for G protein ligand-directed signaling
through b2AR. This mechanism for the b2AR may serve as
a model for other GPCR signaling, and the HDX profiles devel-
oped here for functionally selective ligands provide a platform
for discovery of novel b2AR modulators.EXPERIMENTAL PROCEDURES
Reagents and Chemicals
HPLC grade H2O, D2O (99.9%), acetonitrile, formic acid, iso-propanol, tris-
(carboxyethyl)-phosphinehydrochloride (TCEP), iodoacetamide, Tris, NaCl,
NaH2PO4, glycerol, and anti-FLAG antibody were purchased from Sigma-
Aldrich (St. Louis, MO). Trifluoroacetic acid (TFA, Sequanal grade) was
obtained from Pierce (Rockford, IL). High purity n-dodecyl-b-D-maltoside
(DDM) and cholesterol hemisuccinate (CHS) were purchased from Anatrace
Inc. (Maumee, OH). PNGase F at 500 000 unit/ml was purchased from New
England BioLabs Inc. (Ipswich, MA). The porcine pepsin-immobilized POROS
20 AL beads (particle size 20 mm) used to pack immobilized pepsin columns
were purchased from Applied Biosystems (Foster City, CA).
Expression and Purification of b2AR
Human b2AR containing an N-terminal FLAG tag and a C-terminal 10xHis tag
with E122W and N187E mutations with shortened ICL3 and C terminus (resi-
dues 245–259, 349–413 were deleted) was expressed in Sf9 insect cells as
previously described (Hanson et al., 2008). Cells were lysed in hypotonic buffer
(20 mM HEPES [pH 7.5], 20 mM KCl, 10 mMMgCl2) and the membranes were
washed five times in high salt buffer (50 mM HEPES [pH 7.5], 500 mM NaCl,
10% glycerol). Membranes were flash-frozen and stored at80C until further
use. All subsequent purification steps were carried out on ice or at 4C. For
purification, membranes were thawed and incubated with 1 mM timolol
(Sigma) in the presence of complete EDTA-free protease inhibitors (Roche),
and 2 mg/ml iodoacetamide (Sigma) to block exposed cysteines prior to solu-
bilization with 0.5% n-dodecyl-b-D-maltopyranoside (DDM, Anatrace) and
0.1% cholesterol hemisuccinate (CHS, Sigma) for 4 hr. Solubilized proteins1430 Structure 19, 1424–1432, October 12, 2011 ª2011 Elsevier Ltdwere incubated with Co2+ charged TALON IMAC resin (Clontech) for 4 hr,
then washed with 10 column volumes (CV) of wash buffer (50 mM HEPES
[pH 7.5], 20 mM imidazole, 500 mM NaCl, 0.05% DDM, 0.01% CHS, 10%
glycerol) with 1 mM timolol. The receptor was deglycosylated while still bound
to the resin overnight by addition of PNGaseF (New England Biolabs). On the
following day, timolol was exchanged for the target compounds (-)-isoproter-
enol (Sigma), clenbuterol (Sigma), alprenolol (Sigma), or carazolol (Toronto
Research Chemicals), by washing the resin with 20–25 CV of wash buffer con-
taining 1 mM of target compound. b2AR-ligand complexes were then eluted
with elution buffer (50 mM HEPES [pH 7.5], 200 mM imidazole, 500 mM
NaCl, 0.05% DDM, 0.01% CHS, 10% glycerol) containing 1 mM of the target
compound. For apo b2AR, similar procedures were used except no ligand was
added in the buffers after the PNGaseF treatment. To verify that timolol was
replaced by the target compound, we measured the sample’s thermal stability
(Figure S5B) using the thiol-specific fluorochrome N-[4-(7-diethylamino-
4-methyl-3-coumarinyl)phenyl]maleimide (CPM) as previously described
(Alexandrov et al., 2008). The protein’s purity and monodispersity was deter-
mined by running the samples on the SDS-PAGE gel analytical size exclusion
chromatography. When the purity is >95% pure as indicated by the SDS-
PAGE gel and a single peak with elution profile indicative of monomeric
receptor, the samples were then concentrated toR5 mg/ml (> 120 mM) using
concentrators with 100 kDa molecular weight cutoff (Sartorius), flash-frozen,
and stored at 80C until use.
HDX Analysis of b2AR
Sequence coverage of b2AR was performed in a previous study (Zhang et al.,
2010b). Prior to HDXMS experiments the purified protein was diluted to 15 mM
for mass spectrometry experiments using the buffer composed of 50 mM
HEPES (pH 7.5), 150 mM NaCl, 2% (v/v) glycerol, 0.05% (m/v) DDM, and
0.01% (m/v) CHS in H2O. Except for the apo sample, this buffer also contained
300 mM ligand, a 20-fold excess over receptor concentration, to promote satu-
rating conditions. The buffer for HDX on-exchange was the same composition
except H2O was replaced with D2O (99.9%). For HDX MS experiments, 4 ml of
b2AR protein (with or without ligand) was mixed with 16 ml of the D2O buffer
(final D2O content was 80%), or H2O buffer for t0 samples, i.e., 0 s controls,
and incubated at various time intervals at 4C, before being added to 30 ml
of quench solution. The quench solution contained 100 mM NaH2PO4,
0.02% DDM, and 15 mM TCEP (pH 2.4). Protein samples were then digested
online by passing through an immobilized pepsin-coupled column (2mm i.d.3
20 mm) (Busby et al., 2007). HPLC (Eksigent, Dublin, CA) was performed with
a 9.5 min gradient at flow rate of 50 ml/min with a C8 trap (1 mm i.d., Thermo
Fisher Scientific, San Jose, CA), a C8 column (5 mm packing, 10 3 1 mm,
Thermo Fisher Scientific, San Jose, CA), and 1/32 3 100 mM PEEK tubing.
The mobile phase for the online immobilized pepsin-coupled column was
H2O with 0.1% (v/v) TFA and the flow rate was 50 ml/min. For HPLC, buffer A
was H2O containing 0.3% (v/v) formic acid, buffer B was acetonitrile/water
at 4:1 (v/v) containing 0.3% (v/v) formic acid, and the flow rate was 50 ml/min.
The gradient started with 5% B, increased to 15% B over 0.1 min, increased
to 50% B within 5.4 min, then quickly increased to 98% within 0.5 min, held
for 1.5 min, and decreased back to 5% within 0.1 min. MS was acquired in
the range of m/z 300–2000 for 8 min in positive ion mode on an orbitrap
mass spectrometer (Thermo Fisher Scientific, San Jose, CA) equipped with
an ESI source operated at capillary temperature of 225C and spray voltage
of 3.5 kV. Protein and quench solutions, traps, and HPLC columns were all
kept at 1.0C unless specified otherwise. The online pepsin column was
kept at 15C. HDX incubation was performed at 1.0C for seven different
time points: 10, 30, 60, 300, 900, 3600, and 13,500 s. The experiments were
performed at random order, and, between every two injections, blank injec-
tions were made to remove any potential protein carryover from previous
runs. Two additional incubations (12 and 18 hr) were mixed manually and per-
formed in sealed Eppendorf tubes also at 1C.Data for each on-exchange time
point were obtained in three replicates. All HDX data were normalized to 100%
D2O content, corrected for an estimated average deuterium recovery of 70%,
and processed using the software HD Desktop (Pascal et al., 2009). Statistical
tests were performed with Prism v 5.03 (Graphpad Software) as described
previously (Chalmers et al., 2011b). Percent deuterium incorporation was
plotted versus incubation time in log scale. All on-exchange plots used in
the analysis of b2AR are shown in Figures S4–S8. The HDX profiles of b2ARAll rights reserved
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Modulator Effects on GPCR Conformation Using HDXbound to each ligand were mapped to the construct’s own amino acid
sequence and also a modified crystal structure of human b2AR. The modified
structure is based on PDB 2RH1, but has ICL3 and the termini regions
arbitrarily grafted in to accommodate the sequence coverage in this study
(Cherezov et al., 2007).
Prediction of Initial Amide Proton Accessibility
in the b2AR 3D Structure
Analysis of the initial amide proton accessibility was performed using custom
scripts developed with the ICM molecular modeling package (Molsoft LLC).
A full-length all-atommodel of receptor was prepared from the high-resolution
crystal structure of carazolol bound b2AR (PDB code 2rh1) by adding corre-
sponding N- and C-terminal sequences and loop ICL3, which were modeled
in extended conformations. Fully protonated model was generated by ICM
conversion that adds and energy-optimizes hydrogens, and also selects an
optimal conformer for His, Asn, and Gln side chains. The amide proton in
this model was considered inaccessible if it (1) was involved in a hydrogen
bond within the protein structure, (2) was inaccessible on the protein surface
(buried), or (3) was accessible only to the lipid bilayer interface. We used
a hydrogen bond assignment tool in ICM with cutoff hbond MinStrength =
0.4 and taking into account both main-chain-to-main-chain and side-chain-
to-main-chain hydrogen bonds. No significant changes in results were
observed by varying this parameter within a 0.3–0.5 range. Solvent accessible
amine nitrogens were identified using ICM solvent accessible area tool with
default water radius parameter 1.4 A˚. Membrane region for b2AR was pre-
dicted by OPM server (http://opm.phar.umich.edu) and those amide nitrogens
that belong to the region were considered inaccessible.
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